A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

189

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Peyronie's Disease

Interventions

BIOLOGICAL

AA4500

2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles